I’ve made it no secret over the last few months that I’m very much at odds with the AIDS Health Foundation’s stance on Truvada and PrEP. Their position, put very simply, is “no way” and have mounted a very rigorous campaign against it.
To keep the momentum going on their campaign, AHF commissioned a “ground-breaking” study on people’s perceptions of Truvada, the physical pro’s and con’s, as well as any anticipated costs/doctor visits. Here’s what they’re saying:
AHF’s survey, which was presented yesterday as part of an HIV PrEP Symposium at UCLA, raises questions about the use of Truvada as an HIV prevention pill—or pre-exposure prophylaxis (PrEP). The online focus group was designed to determine “real world” reactions from prospective consumers about taking PrEP and to gain further information about potential adherence issues and the pill’s possible impact on condom use.
Among the findings: 79% of respondents answered “Yes” to the question: “If you could take a pill on a daily basis to prevent HIV, would you take it?” However, only 63% of respondents said they would be “Very Likely” to remember to take the prevention pill every day. The percentage of men who would take the pill decreased significantly when the possible need for frequent doctor visits and co-payments were introduced with only 41% responding “Yes” to taking the pill if it required paying up to $60.00 every month in co-payments and laboratory costs. To view a summary of the study results, please click here.
Full text of article available at link below –